Gemcitabine overcomes erlotinib resistance in EGFR overexpressing cancer cells through downregulation of Akt

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 435-442

  Bartholomeusz, Chandra ^a   Yamasaki, Fumiyuki ^a,b   Saso, Hitomi ^a   Kurisu, Kaoru ^b   Hortobagyi, Gabriel N ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

A 431; Breast cancer; Erlotinib; Gemcitabine; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR;

ADD ON THERAPY; ADVANCED CANCER; ARTICLE; CANCER CELL; CHEMOSENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 84862080029     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.435     Document Type: Article

References (21)

1. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7: 2958-70.
2. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006; 12: 7242-51.
3. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007; 18 (Suppl 6): vi35-vi41.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-32.
5. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007; 14: 295-304.
6. Bunn PA Jr. Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors? J Clin Oncol. 2007; 25: 2504-5.
7. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007; 5: 203-20.
8. Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007; 67: 5779-88.
9. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005; 102: 3788-93.
10. Maiello MR, D'Alessio A, De Luca A, et al. AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat. 2007; 102: 275-82.
11. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther. 2004; 3: 465-72.
12. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97: 880-7.
13. Yamasaki F, Zhang D, Bartholomeusz C, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007; 6: 2168-77.
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
15. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol. 1999; 6: 279-85.
16. Cartee L, Kucera GL, Willingham MC. Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. Apoptosis. 1998; 3: 439-49.
17. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002; 1: 777-83.
18. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res. 2006; 66: 981-8.
19. Feng FY, Varambally S, Tomlins SA, et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007; 26: 3431-9.
20. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006; 66: 10553-9.
21. Ando K, Ohmori T, Inoue F, et al. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. Clin Cancer Res. 2005; 11: 8872-9.